Free Newsletter
Top Story
Colorado researchers remove leukemia's shield, making it easier to kill
Acute myeloid leukemia is almost diabolically adaptable, able to resist chemotherapy and other formidable drug weapons doctors use to fight it. Read more...
Latest News
Nearly $11M to fund new Joslin Diabetes Center research facility
Diabetes research is getting a significant boost in Boston: The Harvard Medical School-affiliated Joslin Diabetes Center will spend $10.8 million to establish a Translational Center for the Cure of Read more...
New target could be key to beating back methamphetamine addiction
As bad as cocaine addiction can be for many, methamphetamine addiction can take hold even more quickly and ruin a patient's health in horrible ways. The heart, the aging process and even sperm Read more...
Scientists build human Alzheimer's neurons in lab
For the first time, scientists have created functional human Alzheimer's disease neurons in the lab. Their key ingredient: Stem cells from the skin of patents who suffer from the terrible Read more...
Fight colon cancer with veggies, plus 2 other discoveries
We've got three new global advances in the battle against colon cancer to tell you about this week. One group of researchers has figured out a possible connection between eating your fruits and Read more...
Genetic analysis yields hypertension clue
Researchers are inching closer to figuring out why people are genetically prone to hypertension, a condition that affects a billion people around the globe. The discovery that may get us there: A Read more...
U.K. team finds gene link for esophageal cancer
Three families with a rare, hereditary condition that eventually erupts into esophageal cancer share something else--a defective gene--that could lead to better treatments for the particularly nasty Read more...
Targeting NKp46 boosts immune response, Innate Pharma believes
In the bid to develop drugs to boost the immune system and fend off various infections, NKp46 may be the next big target. NKp46 is a receptor that helps regulate the immune system's natural killer Read more...
Obama seeks to beat Alzheimer's by 2025
The Obama administration wants the U.S. to figure out how to effectively treat and even prevent Alzheimer's disease by 2025, arguably a medical equivalent of President John F. Kennedy's challenge to Read more...
Popular Comment Threads
Report
Johns Hopkins tapping genomes to find out why so many African-Americans get asthma
No one is sure why as many as 20% of African-Americans have asthma. Kathleen Barnes will lead an effort to solve the medical mystery. Barnes is an immunogeneticist at The Johns Hopkins University's School of Medicine and Bloomberg School of Public Health. She's the principal investigator of a recently launched, four-year plan to sequence the genomes of 1,000 people of African descent. ArticleFrom The Network
Also Noted
Stem Cell Research
> Adult stem cells helped build a better penis in rats, Science is reporting. Story
> Human embryonic stem cells developed by Advanced Cell Technology ($ACTC) helped improve vision in two patients, The New York Times reports. Story
Cancer
> A specific chromosomal abnormality has both prognostic and predictive value for managing the treatment of adult patients with a rare brain tumor, the Radiation Therapy Oncology Group has determined. Release
> Researchers at the Moffitt Cancer Center and the University of South Florida have discovered that interaction between a specific type of immune system cell and myeloid-derived suppressor cells inhibits some T-cell function. Release
Genetics
Read more >>Press Releases
- BWH Researchers Develop New Drug Release Mechanism Utilizing 3D Superhydrophobic Materials
- Discovery of new vaccine approach for treatment of cancer
- Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
- Celator Pharmaceuticals Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia
- New startup out of University of Illinois, Vanquish Oncology, to Develop Personalized Therapeutics for Cancer Markets
- U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal
